

Survival and Prevalence Tables

Table P. 5-Year Relative Survival, 2011-2021, Louisiana

Primary Site ¹	All Race			White					Black		
	Total	Male	Female	Total	Male		Female		Total	Male	Female
All Sites	66.5%	66.3%	66.7%	68.2%	67.7%	↑	68.7%	↑	62.3%	63.1%	61.6%
Oral Cavity and Pharynx	63.0%	62.8%	63.5%	67.9%	68.4%	↑	66.4%	↑	45.4%	43.2%	51.5%
Lip	88.8%	89.2%	84.3%	89.3%	90.3%		82.5%		77.3%	69.5%	100.0%
Tongue	66.4%	66.0%	67.1%	70.5%	70.2%	↑	70.8%	↑	42.9%	42.1%	44.6%
Salivary Gland	71.7%	65.1%	80.9%	68.7%	62.7%		79.2%		78.2%	72.9%	82.5%
Floor of Mouth	46.6%	43.6%	53.3%	52.0%	47.9%	↑	59.0%	↑	32.1%	33.6%	24.2%
Gum and Other Mouth	56.0%	56.7%	54.7%	58.2%	59.8%		55.9%		51.1%	51.2%	50.5%
Nasopharynx	57.4%	56.3%	61.3%	59.3%	57.1%		66.6%		46.1%	47.3%	41.3%
Tonsil	73.1%	74.0%	67.7%	77.5%	78.2%	↑	73.7%	↑	52.5%	54.6%	38.5%
Oropharynx	45.2%	46.6%	40.4%	51.7%	55.6%	↑	39.9%		28.2%	24.3%	42.5%
Hypopharynx	32.2%	30.3%	40.0%	39.5%	38.8%	↑	42.0%		21.3%	19.0%	29.7%
Other Oral Cavity and Pharynx	46.2%	44.9%	50.2%	58.5%	60.2%	↑	48.2%		20.0%	10.1%	47.6%
Digestive System	44.3%	41.5%	47.9%	45.9%	43.4%	↑	49.4%	↑	41.2%	37.8%	45.5%
Esophagus	20.7%	18.7%	28.3%	22.5%	20.2%	↑	32.8%	↑	15.4%	13.8%	19.5%
Stomach	33.1%	30.3%	37.7%	35.7%	33.4%	↑	39.4%		30.5%	26.5%	36.1%
Small Intestine	72.5%	73.1%	71.7%	74.8%	73.0%		76.6%	↑	67.8%	70.8%	64.7%
Colon and Rectum	64.7%	64.1%	65.5%	66.8%	66.4%	↑	67.4%	↑	60.9%	59.5%	62.2%
Colon excluding Rectum	64.7%	64.9%	64.5%	67.3%	67.2%	↑	67.4%	↑	59.9%	60.3%	59.6%
Cecum	63.9%	65.0%	62.9%	66.6%	67.3%		65.9%	↑	59.0%	60.8%	57.6%
Appendix	82.8%	82.6%	82.7%	87.6%	89.0%	↑	86.6%	↑	68.1%	67.4%	68.3%
Ascending Colon	68.4%	66.2%	70.2%	70.2%	67.5%		72.3%		65.5%	64.9%	66.0%
Hepatic Flexure	65.3%	66.1%	64.4%	66.5%	66.9%		65.6%		63.4%	65.1%	61.1%
Transverse Colon	62.2%	60.7%	63.6%	63.3%	63.5%	↑	63.1%		60.1%	55.5%	64.0%
Splenic Flexure	61.9%	64.8%	57.5%	62.2%	63.4%		59.5%		61.6%	65.5%	56.3%
Descending Colon	65.6%	67.1%	63.7%	67.9%	69.8%		64.8%		61.8%	61.7%	61.7%
Sigmoid Colon	66.9%	67.7%	65.9%	69.8%	69.9%	↑	69.7%	↑	60.8%	62.1%	59.4%
Large Intestine, NOS	27.5%	30.2%	24.5%	26.7%	29.7%		23.3%		28.5%	30.4%	26.3%
Rectum and Rectosigmoid Junction	65.0%	62.7%	68.2%	66.0%	64.9%	↑	67.5%		63.2%	58.0%	69.7%
Rectosigmoid Junction	58.5%	56.9%	60.5%	61.7%	61.7%	↑	61.7%		51.3%	46.3%	57.6%
Rectum	66.6%	64.1%	70.1%	67.1%	65.7%	↑	69.1%		65.8%	60.7%	72.2%
Anus, Anal Canal and Anorectum	70.3%	62.9%	75.0%	72.7%	63.1%		78.0%	↑	63.7%	60.9%	65.8%
Liver and Intrahepatic Bile Duct	17.3%	16.8%	18.9%	18.2%	17.7%	↑	19.9%		14.3%	14.0%	15.5%
Liver	18.7%	17.9%	21.7%	20.1%	19.1%	↑	23.9%		15.0%	14.6%	17.0%
Intrahepatic Bile Duct	6.6%	4.2%	9.1%	6.3%	4.4%	↓	8.3%		5.7%	4.5%	8.5%
Gallbladder	18.7%	13.6%	21.1%	19.7%	15.3%		21.8%		15.7%	12.4%	17.1%
Other Biliary	16.8%	15.7%	17.7%	17.1%	15.1%		19.1%		15.6%	15.3%	15.8%
Pancreas	9.4%	9.1%	9.8%	9.5%	9.5%	↑	9.5%		9.1%	7.7%	10.4%
Retroperitoneum	54.1%	52.1%	55.3%	54.2%	50.9%		57.3%		50.5%	35.0%	53.7%
Peritoneum, Omentum and Mesentery	27.6%	10.3%	29.4%	28.1%	13.5%		29.6%		23.7%	0.0%	26.3%
Other Digestive Organs	11.4%	10.3%	12.3%	9.4%	10.5%		7.9%		15.3%	9.5%	18.6%

Respiratory System	24.4%	22.9%	26.4%	24.9%	23.2%		27.0%		22.9%	22.1%	24.2%
Nose, Nasal Cavity and Middle Ear	64.3%	65.0%	63.0%	67.5%	68.2%		66.3%		53.4%	53.4%	49.9%
Larynx	58.1%	58.9%	55.3%	60.0%	60.3%	↑	58.5%	↑	53.9%	55.3%	47.9%
Lung and Bronchus	21.1%	18.1%	24.7%	21.7%	18.5%		25.4%		19.3%	17.1%	22.5%
Pleura	13.2%	0.0%	24.3%	15.7%	0.0%		30.6%		0.0%	0.0%	0.0%
Trachea, Mediastinum and Other Respiratory	40.7%	41.2%	41.7%	45.3%	51.5%		39.9%		36.4%	34.2%	41.9%
Bones and Joints	65.8%	63.7%	68.0%	66.3%	61.9%		70.1%		62.4%	61.3%	63.3%
Soft Tissue including Heart	65.2%	66.0%	64.0%	67.7%	68.2%		67.0%		59.8%	61.8%	57.9%
Skin excluding Basal and Squamous	93.6%	92.4%	95.5%	94.0%	92.7%	↑	95.9%	↑	81.2%	75.4%	85.6%
Melanoma of the Skin	94.1%	93.0%	95.7%	94.5%	93.4%	↑	96.3%	↑	66.4%	61.5%	70.3%
Other Non-Epithelial Skin	89.5%	86.5%	92.0%	87.7%	85.4%		89.6%		92.9%	86.3%	94.8%
Breast	89.2%	76.9%	89.3%	92.0%	78.5%		92.1%	↑	83.5%	73.0%	83.6%
Female Genital System	65.9%	--	65.9%	70.1%	--		70.1%	↑	56.9%	--	56.9%
Cervix Uteri	64.4%	--	64.4%	67.6%	--		67.6%	↑	57.7%	--	57.7%
Corpus and Uterus, NOS	75.5%	--	75.5%	82.8%	--		82.8%	↑	62.0%	--	62.0%
Corpus Uteri	77.4%	--	77.4%	84.2%	--		84.2%	↑	64.5%	--	64.5%
Uterus, NOS	20.8%	--	20.8%	23.6%	--		23.6%		16.9%	--	16.9%
Ovary	46.3%	--	46.3%	48.3%	--		48.3%	↑	40.5%	--	40.5%
Vagina	46.9%	--	46.9%	48.6%	--		48.6%		47.0%	--	47.0%
Vulva	73.6%	--	73.6%	74.9%	--		74.9%		68.9%	--	68.9%
Other Female Genital Organs	43.5%	--	43.5%	45.7%	--		45.7%		36.0%	--	36.0%
Male Genital System	99.7%	99.7%	--	99.9%	99.9%	↑	--		98.5%	98.5%	--
Prostate	99.8%	99.8%	--	99.9%	99.9%	↑	--		98.9%	98.9%	--
Testis	96.5%	96.5%	--	97.6%	97.6%	↑	--		89.4%	89.4%	--
Penis	67.8%	67.8%	--	71.7%	71.7%		--		60.4%	60.4%	--
Other Male Genital Organs	84.9%	84.9%	--	99.4%	99.4%	↑	--		54.6%	54.6%	--
Urinary System	77.1%	77.6%	76.1%	78.6%	79.0%	↑	77.5%	↑	72.2%	72.2%	72.3%
Urinary Bladder	78.6%	80.4%	72.8%	80.5%	81.6%	↑	76.6%	↑	68.3%	73.2%	57.8%
Kidney and Renal Pelvis	77.0%	75.9%	78.9%	77.9%	77.2%	↑	79.1%		75.0%	72.2%	78.7%
Ureter	48.4%	47.5%	49.2%	48.5%	47.8%		49.3%		44.9%	41.7%	47.9%
Other Urinary Organs	47.7%	55.2%	34.9%	52.4%	58.1%		40.5%		37.4%	46.6%	26.5%
Eye and Orbit	81.4%	81.7%	81.1%	81.1%	82.3%		79.6%		83.5%	77.6%	91.9%
Brain and Other Nervous System	32.3%	30.7%	34.2%	30.5%	29.6%		31.7%	↓	35.0%	31.0%	40.0%
Brain	29.3%	28.2%	30.7%	27.8%	27.3%		28.4%		31.9%	28.8%	35.9%
Cranial Nerves Other Nervous System	78.1%	74.6%	81.8%	78.2%	74.2%		82.7%		74.1%	64.4%	79.8%
Endocrine System	97.5%	94.7%	98.3%	98.1%	96.1%	↑	98.7%	↑	95.2%	90.3%	96.3%
Thyroid	98.7%	97.3%	99.1%	99.0%	97.9%		99.3%	↑	97.7%	96.3%	97.8%
Other Endocrine including Thymus	70.0%	70.3%	69.3%	66.5%	67.6%		65.1%		74.1%	74.1%	73.7%
Lymphoma	73.1%	71.4%	75.2%	74.7%	73.4%	↑	76.2%	↑	68.9%	66.0%	72.1%
Hodgkin Lymphoma	86.4%	84.8%	88.3%	86.0%	85.0%		87.1%		87.2%	83.9%	90.9%
Hodgkin - Nodal	87.0%	85.5%	88.7%	86.7%	85.7%		87.6%		87.6%	84.4%	90.9%
Hodgkin - Extranodal	47.3%	43.1%	57.3%	41.7%	20.8%		57.3%		61.4%	61.4%	^
Non-Hodgkin Lymphoma	71.1%	69.3%	73.2%	73.2%	71.8%	↑	74.7%	↑	64.8%	61.5%	68.4%
NHL - Nodal	68.4%	65.9%	71.3%	70.7%	68.4%	↑	73.4%	↑	60.0%	57.6%	62.5%
NHL - Extranodal	76.3%	75.8%	76.7%	77.7%	78.4%	↑	76.9%		72.8%	68.5%	76.7%
Myeloma	57.4%	57.1%	57.7%	57.3%	58.1%		56.0%		57.0%	54.9%	58.9%

Leukemia	65.5%	65.0%	66.0%	67.1%	66.2%	↑	68.3%	↑	59.9%	60.9%	58.6%
Lymphocytic Leukemia	85.4%	83.6%	88.0%	87.1%	85.2%	↑	89.8%	↑	78.9%	78.4%	79.7%
Acute Lymphocytic Leukemia	70.1%	67.7%	72.7%	71.6%	70.8%		72.4%		65.3%	60.9%	71.2%
Chronic Lymphocytic Leukemia	89.6%	87.4%	92.7%	90.4%	87.8%		94.2%	↑	84.1%	84.5%	83.5%
Other Lymphocytic Leukemia	83.7%	83.3%	83.9%	85.6%	84.7%		87.3%		71.8%	72.9%	68.1%
Myeloid and Monocytic Leukemia	41.5%	39.9%	43.4%	40.4%	38.1%		43.1%		43.2%	42.3%	44.0%
Acute Myeloid Leukemia	26.0%	24.7%	27.4%	24.1%	21.1%	↓	27.6%		29.0%	31.3%	26.2%
Acute Monocytic Leukemia	19.9%	27.7%	5.9%	20.9%	30.8%		6.8%		11.9%	12.6%	0.0%
Chronic Myeloid Leukemia	67.8%	65.2%	70.7%	66.4%	64.9%		68.2%		70.2%	63.0%	78.1%
Other Myeloid/Monocytic Leukemia	33.1%	26.0%	41.7%	34.1%	32.9%		36.1%		12.8%	0.0%	51.1%
Other Leukemia	54.8%	58.5%	49.8%	53.8%	57.4%		48.8%		57.6%	61.2%	54.1%
Other Acute Leukemia	29.9%	24.6%	36.3%	30.1%	23.4%		37.7%		25.8%	^	38.1%
Aleukemic, Subleukemic and NOS	64.8%	72.9%	55.2%	62.7%	70.1%		53.2%		70.0%	82.3%	59.0%
Mesothelioma	10.3%	6.4%	19.1%	10.4%	6.8%		18.6%		8.3%	2.5%	21.7%
Kaposi Sarcoma	67.0%	66.9%	64.7%	85.3%	83.7%	↑	89.0%	↑	51.9%	53.5%	^
Miscellaneous	40.2%	38.5%	42.0%	42.4%	41.9%	↑	42.9%	↑	34.3%	29.1%	39.1%

¹Except for urinary bladder (in situ and invasive), only invasive cases are included.

^The statistic could not be calculated.

↑ or ↓ Within Louisiana, white sex-specific relative survival is significantly ($p < 0.05$) higher or lower than black sex-specific relative survival.

--Not applicable.

Table Q. Louisiana Prevalence Counts by Region, Invasive Cancers Only, January 1, 2022^{1,2}

Site/Region	Louisiana	New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
All Sites	204,696	38,538	42,849	30,500	28,526	12,892	12,695	24,520	14,681
Oral Cavity and Pharynx	5,408	908	1,127	835	761	361	359	661	400
Esophagus	702	122	141	116	89	49	55	89	42
Stomach	1,681	398	351	234	231	85	100	184	98
Colon and Rectum	20,019	3,603	3,917	2,705	3,028	1,309	1,394	2,491	1,581
Liver and Intrahepatic Bile Duct	1,541	446	308	240	190	86	41	157	73
Pancreas	1,306	273	259	236	174	63	69	153	80
Larynx	1,996	376	402	288	293	125	113	267	131
Lung and Bronchus	9,477	1,858	1,839	1,404	1,411	584	619	1,077	695
Melanoma of the Skin	10,344	1,577	2,492	1,777	1,161	717	609	1,122	902
Breast	42,556	8,711	8,697	6,391	6,074	2,471	2,259	5,016	2,996
Cervix Uteri	2,539	491	486	326	366	178	168	349	177
Corpus and Uterus, NOS	6,465	1,235	1,245	887	908	405	429	862	494
Ovary	1,813	369	415	298	228	113	106	183	100
Prostate	48,504	8,953	11,138	6,576	6,706	3,008	2,890	5,872	3,359
Testis	1,873	352	403	277	258	141	130	195	120
Urinary Bladder	8,236	1,520	1,647	1,428	1,093	518	554	972	508
Kidney and Renal Pelvis	11,023	1,948	2,293	1,744	1,667	696	688	1,229	768
Brain and Other Nervous System	1,566	293	325	248	213	101	114	169	103
Thyroid	9,542	1,628	1,794	1,483	1,451	605	684	1,149	749
Hodgkin Lymphoma	2,006	385	393	319	278	133	141	230	127
Non-Hodgkin Lymphoma	8,912	1,746	1,767	1,424	1,232	627	541	1,020	555
Myeloma	2,683	557	595	396	292	138	136	367	204
Leukemia	5,643	898	1,088	886	819	404	385	745	419
Acute Lymphocytic Leukemia	829	146	183	131	120	57	46	95	51
Mesothelioma	119	31	29	24	12	10	^	^	^
Kaposi Sarcoma	224	97	50	14	22	10	^	18	9

¹ January 1, 2022, 22-Year Limited Duration Prevalence counts are based on 2022 cancer prevalence proportions from SEER 17 registries. Populations were estimated by averaging 2021 and 2022 populations.

²Inclusion methods: For all sites, we count first invasive tumor for each person diagnosed during the previous 22 years (2000-2021). For each specific cancer site, we count first invasive tumor for each site diagnosed during the previous 22 years (2000-2021).

³ Breast tumor includes both sexes. ⁴ Urinary bladder category includes urinary bladder tumor in situ. ^Statistic not displayed due to fewer than 6 prevalent cases.

Table R. Louisiana Prevalence Counts by Age Group, Invasive Cancers
Only, January 1, 2022^{1,2}

Site/Ages	All ages	0-19	20-39	40-49	50-59	60-69	70-79	80-89
All Sites	204,696	3,559	16,056	25,359	53,464	67,690	37,575	9,872
Oral Cavity and Pharynx	5,408	48	304	752	1,736	1,666	774	220
Esophagus	702	^	12	56	170	260	166	40
Stomach	1,681	8	89	175	406	564	351	100
Colon and Rectum	20,019	57	924	2,324	5,868	6,191	3,615	1,194
Liver and Intrahepatic Bile Duct	1,541	45	27	72	395	653	295	57
Pancreas	1,306	^	64	104	299	436	314	87
Larynx	1,996	^	46	222	605	715	328	85
Lung and Bronchus	9,477	9	136	460	1,908	3,592	2,723	827
Melanoma of the Skin	10,344	115	1,519	1,613	2,387	2,534	1,727	619
Breast	42,556	^	2,639	7,723	11,698	12,419	6,987	2,047
Cervix Uteri	2,539	^	937	718	499	274	82	27
Corpus and Uterus, NOS	6,465	^	419	873	1,921	2,189	900	159
Ovary	1,813	57	266	309	463	422	224	73
Prostate	48,504	^	44	1,722	12,640	22,361	10,330	1,405
Testis	1,873	96	1,200	368	166	36	9	^
Urinary Bladder	8,236	9	170	504	1,662	2,822	2,298	830
Kidney and Renal Pelvis	11,023	184	618	1,548	2,936	3,489	1,930	431
Brain and Other Nervous System	1,566	564	394	216	174	132	74	17
Thyroid	9,542	175	2,503	2,096	2,258	1,711	696	112
Hodgkin Lymphoma	2,006	293	977	292	225	133	63	22
Non-Hodgkin Lymphoma	8,912	250	918	1,019	1,982	2,505	1,787	530
Myeloma	2,683	^	68	253	599	923	632	212
Leukemia	5,643	833	510	533	1,055	1,373	965	380
Acute Lymphocytic Leukemia	829	644	78	27	41	24	12	^
Mesothelioma	119	^	11	13	18	29	36	10
Kaposi Sarcoma	224	^	104	47	29	19	14	11

¹ January 1, 2022, 22-Year Limited Duration Prevalence. Populations were estimated by averaging 2021 and 2022 populations.

² Inclusion methods: For all sites, we count first invasive tumor for each person diagnosed during the previous 22 years (2000-2021). For each specific cancer site, we count first invasive tumor for each site diagnosed during the previous 22 years (2000-2021).

³ Breast tumor includes both sexes.

⁴ Urinary bladder category includes urinary bladder tumor in situ.

^Statistic not displayed due to fewer than 6 prevalent cases.

Other Tables

Table S. Percent of Cases^{1,2} with Microscopic Confirmation by Primary Site, All Races and Both Sexes Combined, 2018-2022, Louisiana

	Microscopically Confirmed	All Cases	Percent Microscopically Confirmed
All Sites	128,366	136,298	94.2%
Oral Cavity and Pharynx	3,771	3,824	98.6%
Esophagus	1,312	1,344	97.6%
Stomach	1,953	1,994	97.9%
Small Intestine	949	962	98.6%
Colon and Rectum	11,751	12,046	97.6%
Colon excluding Rectum	8,121	8,360	97.1%
Rectum and Rectosigmoid Junction	3,630	3,686	98.5%
Liver	1,479	2,749	53.8%
Pancreas	3,647	4,207	86.7%
Larynx	1,365	1,381	98.8%
Lung and Bronchus	15,905	17,697	89.9%
Melanoma of the Skin	4,900	4,914	99.7%
Breast	18,788	18,949	99.2%
Corpus and Uterus, NOS	3,220	3,265	98.6%
Ovary	1,146	1,216	94.2%
Prostate	20,450	20,790	98.4%
Urinary Bladder	4,970	5,040	98.6%
Kidney and Renal Pelvis	5,928	6,549	90.5%
Brain and Other Nervous System	1,277	1,445	88.4%
Thyroid	3,133	3,146	99.6%
Hodgkin Lymphoma	644	649	99.2%
Non-Hodgkin Lymphoma	4,946	5,068	97.6%
Myeloma	1,996	2,397	83.3%
Leukemia	3,578	3,831	93.4%
Mesothelioma	271	279	97.1%
Kaposi Sarcoma	113	116	97.4%

¹Case counts represent the total combined number of cases for the 5-year period.

²Except for urinary bladder (in situ and invasive), only invasive cases are included.